Clinical Data Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Clinical Data Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who wrote (26)	9/5/2007 12:42:58 PM
From: Jim Oravetz	Read Replies (1) of 39

Clinical Data Drepression Drug Vilazodone Met Trial Endpoints DOW JONES NEWSWIRES September 4, 2007 9:25 a.m. DOW JONES NEWSWIRES Clinical Data Inc. (CLDA) said its investigative compound Vilazodone demonstrated positive results in a Phase III study for depression. The Newton, Mass.-based provider of products and consulting services to the physician office laboratory market said the primary and supportive secondary efficacy endpoints were met. In addition, the study separately identified candidate biomarkers for a potential companion pharmacogenetic test for response to Vilazodone. Vilazodone combines the mechanisms of action of both a selective serotonin reuptake inhibitor and a 5HT1A partial agonist, making it the only compound which combines two mechanisms used as first and second line treatments for mood disorders. Clinical Data plans to meet with the U.S. Food and Drug Administration to discuss the remaining trials needed support an NDA filing. The company said it plans to aggressively pursue its development program for Vilazodone.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next